S&P 500
(0.02%) 5 071.63 points
Dow Jones
(-0.11%) 38 461 points
Nasdaq
(0.10%) 15 713 points
Oil
(-0.18%) $82.66
Gas
(0.54%) $1.662
Gold
(-0.29%) $2 331.60
Silver
(-0.35%) $27.25
Platinum
(-0.38%) $912.30
USD/EUR
(-0.05%) $0.934
USD/NOK
(-0.06%) $10.98
USD/GBP
(-0.01%) $0.802
USD/RUB
(0.00%) $92.32

Realtime updates for NGM Biopharmaceuticals [NGM]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
50.00%
return 2.17%
SELL
50.00%
return -2.24%
Last Updated4 Apr 2024 @ 16:00

0.00% $ 1.540

BUY 101140 min ago

@ $1.435

Issued: 14 Feb 2024 @ 15:31


Return: 7.32%


Previous signal: Feb 14 - 09:52


Previous signal: Sell


Return: -3.68 %

Live Chart Being Loaded With Signals

Commentary (4 Apr 2024 @ 16:00):
Profile picture for NGM Biopharmaceuticals Inc

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer...

Stats
Today's Volume 0.00
Average Volume 969 866
Market Cap 128.53M
EPS $0 ( 2024-03-12 )
Next earnings date ( $-0.300 ) 2024-05-02
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -0.890
ATR14 $0.00400 (0.26%)
Insider Trading
Date Person Action Amount type
2024-04-05 Tcg Opportunity Iii Gp, Llc Buy 1 000 Common Stock
2024-04-05 Tcg Opportunity Iii Gp, Llc Sell 44 000 Common Stock
2024-04-05 Column Group Gp, Lp Buy 1 000 Common Stock
2024-04-05 Column Group Gp, Lp Sell 44 000 Common Stock
2024-04-05 Column Group L P Buy 1 000 Common Stock
INSIDER POWER
-56.32
Last 100 transactions
Buy: 3 241 050 | Sell: 9 885 031

Volume Correlation

Long: -0.36 (neutral)
Short: 0.00 (neutral)
Signal:(48.109) Neutral

NGM Biopharmaceuticals Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

NGM Biopharmaceuticals Correlation - Currency/Commodity

The country flag 0.49
( neutral )
The country flag 0.73
( moderate )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.76
( moderate )

NGM Biopharmaceuticals Financials

Annual 2023
Revenue: $4.42M
Gross Profit: $2.20M (49.72 %)
EPS: $-1.730
Q4 2023
Revenue: $165 000
Gross Profit: $-353 000 (-213.94 %)
EPS: $-0.330
Q3 2023
Revenue: $582 000
Gross Profit: $82 000.00 (14.09 %)
EPS: $-0.350
Q2 2023
Revenue: $1.42M
Gross Profit: $304 000 (21.36 %)
EPS: $-0.460

Financial Reports:

No articles found.

NGM Biopharmaceuticals

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck & Co., Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators